Chief Science Officer, BIOLIFE4D , Houston, TX, United States
Corresponding author details:
Ravi K. Birla, Ph.D., Chief Science Officer
BIOLIFE4D
2450 Holcombe Blvd
TX,United States
Copyright: © 2020 Birla RK. This is an openaccess article distributed under the terms of the Creative Commons Attribution 4.0 international License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
During the Fontan procedure in congenital heart surgery, an inert passive tubular
graft is used as a flow conduit between the inferior vena cava and pulmonary artery. This
tubular graft does not provide any functional support. Recent advances in the field of tissue
engineering has led to the development of biological Fontan pumps, by coupling contractile
cardiomyocytes surrounding a tubular graft. These biological Fontan pumps are pulsatile
and can lead to functional support within the Fontan circuit. This will be a significant
advancement in congenital heart surgery. This review article will provide insight into the
development of biological Fontan pumps, along with scientific and technological hurdles
that need to be overcome to facilitate the use of these pumps clinically.
Heart failure remains a major cause of mortality globally and in the case of end-stage heart
failure, a heart transplantation is the only real solution. While heart transplantation is used
in case of chronic heart failure, there are other treatment modalities that are implemented
during earlier stages of acute heart failure, including the use of pharmacological agents
which are known to restore heart muscle contractility. Given the high degree of mortality
associated with heart failure, there are now many different strategies being development
to help this patient population, with cardiac tissue engineering being one such treatment
modality. Cardiac tissue engineering strategies are focused on bioengineering contractile
tissue by culturing contracting cardiomyocytes within a complex 3-dimensional (3D)
extracellular matrix [1]. The resulting bioengineered tissue is then conditioned using
bioreactors for electromechanical stimulation and perfusion to support functional
maturation of the bioengineered tissue [2-6]. The field of cardiac tissue engineering has
now expanded and now includes many different methods to bioengineer functional cardiac
patches [7-15]. In addition to cardiac patches, recent advances in the field have resulted in
the fabrication of biological Fontan pumps [16-26], bioengineered ventricles [26-33] and
even whole hearts [34-38] (Figure 1). There have been recent reviews that cover cardiac
patches [39-42] and whole hearts [43]; however, there are no review articles that cover
the field of biological pumps. As a result, this review will focus exclusively on the field of
biological pumps with the following objectives: 1) Describe the process to bioengineer
biological pumps, 2) Discuss different methods to bioengineer biological pumps based on
published literature, 3) Illustrate the potential use of biological pumps as Fontan pumps
for surgical reconstruction for congenital heart patients and 4) Describe scientific and
technological challenges in the field that need to be overcome for the field of Fontan pumps
to move forward towards potential clinical applications.
Figure 1: Overview of Cardiac Tissue Engineering – the field
consists of methods to bioengineer heart muscle, Fontan pumps,
ventricles and whole hearts.
There is no standardized process to bioengineer biological pumps. However, there are
now close to a dozen publications in the field and this collective body of work has provided
a roadmap to bioengineer biological pumps. This is illustrated in Figure 2. The first step
in the process in cell sourcing and many different cell types have now been used. Animal
derived cells are often sourced in the form of ventricular cardiomyocytes (CMs) obtained
from neonatal rat hearts. These cells have frequently been used for model developmental
and validation and for initial proof of concept studies. While animal derived cells cannot
be used for any clinical applications, they can prove to be advantageous for initial proof
of concept studies. During initial stages of model development, there is a need to test and
validate many different process variables and often times, requires a large number of cells.
This requirement can easily be satisfied through the use of animal derived cells, as stem
cells and other human sources are expensive to work with. After initial proof of concepts
have been completed using animal derived cells, the next step is to move towards human
cells and the most common cell source induced pluripotent stem cells (iPSCs) that can be
converted to CMs. iPSC derived CMs have become the gold standard in the field of tissue
and organ fabrication and there are now well-established protocols for the culture and
expansion of iPSCs and also for the conversion of iPSCs to contracting CMs. The next step in
the process is to couple the contractile CMs with a biomaterial, designed and developed to simulate the properties of the mammalian extracellular matrix (ECM).
Type I collagen has been used extensively for these applications,
as this is the major component of mammalian cardiac ECM. Other
biomaterials have also been used an include gelatin and chitosan.
Next, the contractile cells are combined with the biomaterial to form
biological Fontan pumps. There are now many different published
methods to achieve this and will be described in more detail in a later
section; however, current tissue fabrication technologies include
self-organization, cell sheet engineering and use of custom molds as
scaffolds. The goal of this process is to couple the contractile CMs with
the biomaterial to form a tubular graft with concentric organization
of CMs, thereby supporting pulsatile function of the biological pump
in response to CM contraction. The final step in the process is the use
of bioreactors for electromechanical conditioning of the biological
pumps. Bioreactors are devices designed to recapitulate complex
in vivo signals during in vitro culture. This sequential process leads
to the formation of biological Fontan pumps, that are capable of
generating intraluminal pressure upon CM contractions. There are
numerous applications of these Fontan pumps, as described in the
next section.
Figure 2: Process to Fabricate Biological Fontan Pumps –
Contractile CMs are combined with biomaterials to form Biological
Fontan Pumps that are conditioned using bioreactors for coupled
electromechanical stimulation.
The most important application of biological pumps is as Fontan Pumps in cases of hypoplastic left heart syndrome (HLHS) cases in pediatric patients [44]. HLHS is a congenital disorder and is associated with an underdeveloped left ventricle at the time of birth. In most cases, the condition is diagnosed in utero [44]. If left untreated, HLHS almost always results in mortality.
However, with recent advances in congenital heart surgery,
a series of three surgical procedures are now performed, with a
very high success rate at tertiary care centers. A series of three
very delicate surgeries are performed, Norwood, Glenn and Fontan
procedures [44]. In the Norwood procedure, an underdeveloped
aorta is joined with the pulmonary artery, the patent ductus arterioles
(PDA) is removed and a shunt is used to deliver blood to the lungs.
In the Glenn procedure the superior vena cava is connected to the
pulmonary artery and the Norwood shunt is removed. In the Fontan
procedure, the inferior vena cava is connected to the pulmonary
artery using an inert Gore-Tex graft. This tubular graft is inert and
does not provide any pulsatile support to move the patient’s blood
from the inferior vena cava to the pulmonary artery. This results in
severe challenges for the pediatric patient and is known to result in
exercise fatigue and can lead to progressive heart failure over time.
This is where biological Fontan pumps will prove to be beneficial.
Once we can generate an autologous Fontan pump from patient
derived cells, this biological Fontan pump can be used in place of the
inert Gore-Tex tube and provide pulsatile support in moving blood to
the pulmonary arteries. This solution will provide a more biological
solution in place of the current inert Gore-Tex grafts in use and is
expected to solve the problems associated with exercise fatigue and
progressive heart failure. This will be a game changing solution in the
field of congenital heart surgery and one that will help many patients
with HLHS (Figure 3).
Figure 3: Biological Fontan Pumps in the Fontan Circuit
(A) Current Solution – a passive inert Gore-Tex tubular graft is
used between the inferior vena cava and the pulmonary artery.
This tubular graft provides a flow path, with no pulsatile support.
(B) Proposed Solution – a biological Fontan pump can be
bioengineered using patient derived autologous cells. This pump
will then be positioned in between the inferior vena cava and the
pulmonary artery, in place of the GoreTex graft. However, this
biological pump will be contractile and provide pulsatile support
in moving blood from the inferior vena cava to the pulmonary
artery.
There have been several important studies in the field of biological Fontan pumps [16-26], Table 1, though the field is still at a stage of infancy. However, these studies serve to demonstrate the feasibility of this technology and its potential applications in the field of congenital heart surgery.
There have been several publications describing the fabrication of biological pumps using cell sheet engineering [22,25]. The idea is to culture contractile CMs as a cell monolayer on the surface that has been coated with a temperature responsive polymer, poly (Nisopropylacrylamide), (PIPAAm), which changes from hydrophilic to hydrophobic surface by reducing the temperature and this in turns, causes detachment of the cohesive cell monolayer as a sheet of cells. In this study, neonatal ventricular rat myocytes (NVRMs) were used to generate cell sheets, which were then wrapped around an adult rat thoracic aorta and then transplanted in the position of the abdominal aorta in recipient rats for a period of 4 weeks [22]. Upon explantation, the transplanted tissue had formed a highly functional pulsatile pump and shown to generate intraluminal pressures of 5.9 +/- 1.7 mmHg [22]. This same technology was later applied using iPS derived CMs, though the resulting pressures were much lower and in the order of 0.1- 0.2 mmHg [25]. The novelty of this technology lies in the use of the temperature sensitive polymer that supports the formation of cohesive cell sheets, which can then be used to bioengineer biological Fontan pumps.
In another study, engineered heart tissue, referred to as EHTs, were cast into the form of a balloon, by suspending NVRMs in type I collagen, maintained in culture for a period of time and then implanted over the left and right ventricles of uninjured rat hearts for 14 days [26]. The results of this study indicated stability of the tissue construct and viability of the cells after the 14-day implantation study [26]. The novelty of this technology lies in the generation of biological tissue constructs in the shape of a balloon that can be fitted around the external surface of a rodent heart and in theory, provide functional support.
In another study, NVRMs were cultured on the surface of carefully engineered culture surfaces coated with the adhesion protein laminin, to support the formation of a cohesive cell monolayer [18]. After in vitro culture, there was delamination of the cohesive cell monolayer towards the center of the tissue culture plate, where a tubular graft fabricated using chitosan, was positioned [18]. The cohesive cell monolayer anchored to the outer surface of tubular chitosan graft, supporting the formation of a functional biological pump [18]. The novelty of this method lies in the use of self-organization technology to first support the formation of a cohesive and contractile cell monolayer using NVRMs, followed by the use of this newly formed cell monolayer to fabricate biological pumps.
In another study, NVRMs were suspended in a fibrin gel, secured in a tubular chamber and implanted in the thigh region of recipient rats, with the femoral artery and vein positioned in close proximity to the implanted cells [17]. After an implantation period of 3 weeks, the tubular chamber was explanted and the tissue separated, with the isolated cells formed thick vascularized tissue with the femoral artery and vein secured within the explanted tissue [17]. Intraluminal pressure of up to 2 mmHg were demonstrated [17]. The novelty of this method was the utilization of an in vivo environment to support the formation of highly functional and vascularized biological pumps.
NVRMs – neonatal ventricular rat myocytes, iPSC – induced pluripotent stem cell, CMs - cardiomyocytes
Table 1: Strategies to Bioengineer Biological Fontan Pumps
There is now a convincing body of literature, as described in the
previous section, that outlines the development of biological Fontan
pumps. Different cell sources, NVRMs and iPSCCMs have been used,
different biomatrices have been tested and include type I collagen,
fibrin and chitosan and different fabrication strategies have been
implemented and include cell sheet engineering, self-organization,
mold casting and in vivo implantation. The intraluminal pressure has been low in most cases, reported to be under 5 mmHg, which
limits any potential clinical utilization at this stage of development.
Development of this technology towards potential clinical
applications will necessitate the use of iPSC-CMs and precludes any
work with NVRMs. The challenges of large number of high purity and
mature iPSC-CMs will be the most significant hurdle to overcome
in this field. In addition, developing an optimal biomaterial that
functionally integrates with iPSC-CMs, along with bioreactors for
pulsatile flow conditioning and control over the microenvironment,
will be critical to development of biological Fontan pumps that can
be used clinically.
Copyright © 2020 Boffin Access Limited.